Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 15/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | ELANE | P08246 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3895948 | 0.88 | GPBAR1 (0.53) | GPBAR1ELANE | |
| SCHEMBL3883418 | 0.88 | GPBAR1 (0.58) | GPBAR1KMT2APOLBPABPC1LMNA | |
| SCHEMBL3892732 | 0.83 | GPBAR1 (0.54) | GPBAR1KMT2APOLBLMNARECQL | |
| SCHEMBL3885330 | 0.82 | GPBAR1 (0.72) | GPBAR1GAAKMT2APOLBLMNA | |
| SCHEMBL3891191 | 0.79 | GPBAR1 (0.55) | GPBAR1KMT2APOLBLMNARECQL | |
| SCHEMBL3888040 | 0.75 | GPBAR1 (0.51) | GPBAR1KMT2APOLBELANE | |
| SCHEMBL3887529 | 0.74 | HTT (0.73) | GPBAR1LMNA | |
| SCHEMBL3885174 | 0.74 | ROCK1 (0.68) | GPBAR1 | |
| SCHEMBL17478163 | 0.73 | GPBAR1 (0.70) | GPBAR1 | |
| SCHEMBL17478157 | 0.71 | GPBAR1 (1.00) | GPBAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7592357-B2 | Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-09-22 | — | — | US | disclosed |
| US-20080058384-A1 | Novel Compounds | GLAXOSMITHKLINE LLC | 2008-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058384-A1 | Novel Compounds | ARHGDIB, TNK2, ROCK2 | GPBAR1 2826/4885GAA 2742/4885KMT2A 3760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.